Ergoteles LLC Altimmune, Inc. Transaction History

Ergoteles LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$4.19 - $16.83 $176,491 - $708,913	42,122 New	42,122 $177,000
Q2 2022 Aug 12, 2022	BUY	$3.94 - $11.77 $845,918 - $2.53 Million	214,700 New	214,700 $2.51 Million
Q2 2021 Aug 12, 2021	SELL	$9.85 - $16.46 $178,285 - $297,926	-18,100 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$12.71 - $24.31 $230,051 - $440,011	18,100 New	18,100 $256,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $370M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.